Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE SBS 3 long-term safety extension of glepaglutide in short bowel syndrome
NL-OMON58859Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Apr 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Primary endpoint: Incidence and type of adverse events. Started Apr 2022; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NL-OMON58859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58859.